Core Points - Bavarian Nordic A/S has been awarded a joint procurement contract by the European Commission to supply up to 8 million doses of its MVA-BN smallpox/mpox vaccine [1][8] - The two-year agreement, which can be extended for an additional two years, aims to ensure continuous access to the vaccine across Europe, with participation confirmed from the European Commission and 20 countries [2][8] - Approximately 1.1 million doses have already been committed, with the first 750,000 doses expected to be supplied in 2026 [3] Company Overview - Bavarian Nordic is a global vaccine company focused on improving health through innovative vaccines, particularly in the area of smallpox and mpox [7] - The MVA-BN vaccine is the only non-replicating mpox vaccine approved in several countries, including the U.S., Canada, and the EU [6] - The company has been collaborating with HERA since 2022 to support public health responses to mpox outbreaks and to stockpile vaccines against potential smallpox reemergence [5]